Corindus Vascular Robotics (CVRS) Stock Price, News & Analysis

Company Overview

Corindus Vascular Robotics, founded in 2002 and headquartered in Waltham, Massachusetts, is a pioneer in robotic-assisted systems for vascular interventions. The company’s flagship CorPath GRX System enables interventional cardiologists and vascular specialists to perform percutaneous coronary and peripheral procedures with enhanced precision and control. By combining intuitive robotic technology with existing catheterization lab infrastructure, Corindus seeks to transform the way vessel-based therapies are delivered.

The CorPath GRX System integrates seamlessly with standard interventional equipment, offering operators remote control over guidewires, balloons, and stents while reducing exposure to ionizing radiation. Corindus also provides comprehensive training programs, technical support, and procedural planning tools to help healthcare providers optimize workflow and improve patient safety. Ongoing research collaborations and clinical studies aim to expand the system’s indications and demonstrate its value in complex case scenarios.

With a global presence spanning North America, Europe, and the Asia Pacific region, Corindus serves leading hospitals and cardiovascular centers in over 30 countries. The company maintains sales and service offices in key markets and partners with regional distributors to streamline product delivery and on-site support. Corindus’ robotic platforms have been installed in acclaimed medical institutions, reflecting its commitment to advancing minimally invasive treatments worldwide.

Corindus is led by President and Chief Executive Officer Todd M. Jongen, who brings extensive experience in medical technology commercialization and corporate strategy. Supported by a management team with backgrounds in engineering, clinical research, and regulatory affairs, the company continues to invest in innovation to address unmet needs in vascular care. Through strategic partnerships and a focus on evidence-based outcomes, Corindus Vascular Robotics strives to shape the future of interventional therapy.

Key Stats

• Today's Range: $4.27 to $4.27
• 50-Day Range: $4.27 to $4.27
• 52-Week Range: $0.78 to $4.40
• Volume: N/A
• Average Volume: 1.99 million shs
• Market Capitalization: $891.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CVRS Stock Analysis - Frequently Asked Questions

How have CVRS shares performed this year?

Corindus Vascular Robotics' stock was trading at $4.27 at the start of the year. Since then, CVRS stock has increased by 0.0% and is now trading at $4.27.

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) released its earnings results on Tuesday, August, 7th. The medical equipment provider reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider earned $1.67 million during the quarter, compared to analysts' expectations of $3 million.

How do I buy shares of Corindus Vascular Robotics?

Shares of CVRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corindus Vascular Robotics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXDW), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Helios and Matheson Analytics (HMNY) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 7/11/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Medical Appliances & Equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:CVRS
• Previous Symbol: NYSEMKT:CVRS
• CIK: N/A
• Web: www.corindus.com
• Phone: +1-508-6533335
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 208,685,000
• Free Float: N/A
• Market Cap: $891.08 million
• Optionable: Not Optionable
• Beta: N/A